Axsome Therapeutics, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($27.2m) ($28.9m) ($31.0m) ($68.3m) ($102.9m) ($130.4m) ($187.1m) ($239.2m) ($287.2m) ($183.2m)
Depreciation $20k $43k $49k $37k $24k $76k $263k $459k $532k $503k $2.9m
Amortization of Debt Issuance Costs ($65k) ($26k) $470k $554k $668k $1.2m $1.5m $527k
Amortization of Intangible Assets $4.1m $6.4m $6.4m $6.4m
Share-based Payment Arrangement, Noncash Expense $2.0m $2.1m $1.8m $6.1m $14.8m $20.8m $37.7m $62.6m $85.2m $93.8m $93.9m
Payment, Tax Withholding, Share-based Payment Arrangement $176k $532k $1.8m $4.0m $7.1m
Share-based Payment Arrangement, Expense $2.0m $2.1m $1.8m $6.1m $14.8m $20.8m $37.7m $63k $85.2m $93.8m $93.9m
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable $37.7m $57.1m $47.2m $82.5m ($89.7m)
Increase (Decrease) in Inventories $1.3m $8.2m ($744k) $10.7m ($19.3m)
Inventory Write-down $0 $0 $0
Increase (Decrease) in Accounts Payable $2.2m ($646k) $252k $7.3m $2.6m ($355k) $25.5m $2.1m $31.3m ($6.5m) $21.0m
Net Cash Provided by (Used in) Operating Activities ($21.3m)
($26.5m) -24.39%
($30.1m) -13.53%
($46.4m) -54.31%
($78.5m) -69.18%
($108.2m) -37.94%
($116.5m) -7.66%
($145.1m) -24.52%
($128.4m) +11.49%
($93.4m) +27.26%
($70.7m) +24.28%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $105k $10k $33k $16k $46k $308k $702k $582k $270k $480k ($263k)
Net Cash Provided by (Used in) Investing Activities ($105k) ($10k) ($33k) ($16k) ($46k) ($308k) ($53.7m) ($582k) ($270k) ($480k) ($263k)
Cash flows from financing activities:
Repayments of Long-term Debt $3.3m $7.2m $21.7m $332.0m ($404.4m)
Gain (Loss) on Extinguishment of Debt ($1.2m) ($10.4m)
Proceeds from Issuance of Long-term Debt $10.0m $20.0m $50.0m $400.0m
Proceeds from Issuance of Common Stock $23.7m $12.9m $238.2m $14.1m $7.2m $236.8m $258.8m $40.8m $67.9m $54.6m
Net Cash Provided by (Used in) Financing Activities $10.0m
$23.9m +139.61%
$10.0m -57.99%
$252.4m +2415.33%
$42.4m -83.20%
$11.1m -73.76%
$284.6m +2456.96%
$331.0m +16.32%
$57.8m -82.53%
$101.5m +75.42%
$75.2m -25.90%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect ($11.4m) ($2.6m) ($20.1m) $206.0m ($36.1m) ($97.4m) $114.4m $185.4m ($70.8m) $7.6m $305.1m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $200.8m $386.2m $315.4m $322.9m $305.1m
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Proceeds from Stock Options Exercised $33k $317k $380k $1.1m $1.0m $4.4m $6.3m $12.4m $30.7m $59.6m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $47k $865k $772k $1.3m $2.1m $4.6m $7.7m $16.7m $19.7m $14.6m
Income Taxes Paid, Net ($180k)
Additional Financial Items
General and Administrative Expense $6.3m $7.2m $9.4m $13.6m $28.9m $66.6m $54.2m $63.3m
Goodwill $10.3m $12.0m $12.0m $12.0m
Income Tax Expense (Benefit) $0 $0 $0 $0 $0 $960k $85k ($530k)
Operating Expenses $27.5m $27.2m $32.8m $67.2m $99.1m $124.7m
Operating Lease, Expense $1.2m $1.3m $2.2m